Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03423810 · ClinicalTrials.gov registry record · Early Phase 1
Assessing a Dose-Response Relationship of Hydralazine and Its Effects on DNA Methyltransferase 1 in Polycystic Kidney Disease Patients
A Early Phase 1 study, sponsored by University of Kansas Medical Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 14
- Enrollment target
NCT03423810 is a Early Phase 1 study that has completed, run by University of Kansas Medical Center. The registered enrollment target is 14 participants.
The verdict
NCT03423810, a Early Phase 1 study, has completed, sponsored by University of Kansas Medical Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to find a protein (ex. Polycystin 1 or mucin and cadherin like protein) in the urine that is changed after treatment of hydralazine.
Interventions
- DRUG Hydralazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2018-04-23 |
| Est. Completion | 2020-01-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03423810
The ClinicalTrials.gov registry entry for NCT03423810 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hydralazine is the first listed.
NCT03423810 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03423810 about?
NCT03423810 is a clinical study titled "Assessing a Dose-Response Relationship of Hydralazine and Its Effects on DNA Methyltransferase 1 in Polycystic Kidney Disease Patients". The purpose of this study is to find a protein (ex. Polycystin 1 or mucin and cadherin like protein) in the urine that is changed after treatment of hydralazine.
What is the current status of trial NCT03423810?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 14 participants. The study started on 2018-04-23. Estimated completion is 2020-01-30.
What interventions are being tested in trial NCT03423810?
The interventions under investigation include: Hydralazine (DRUG).
Who is sponsoring clinical trial NCT03423810?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.